IASP Releases Position Statement on the Use of Cannabinoids to Treat Pain

chris@csa.co.za
By chris@csa.co.za April 2, 2021 11:14

 

IASP Logo
After a two-and-a-half-year process of rigorous evidence appraisal, the IASP Presidential Task Force on Cannabis and Cannabinoid Analgesia has completed its work. A Position Statement on the use of cannabinoids to treat pain was recently approved by IASP Council and is available in PAIN. A non-technical version of the position statement is available for the benefit of the general public and people with a lived experience of pain.
PAIN also includes a special section with 13 papers which the Task Force members have generated to synthesize the preclinical and clinical evidence relating to cannabinoid-mediated analgesia. These papers form the core materials and conclusion which were used to inform the Position Statement and include four systematic reviews.
We invite you to register for a special virtual workshop during the IASP Virtual Series on Pain, Highlights from the IASP Presidential Task Force on Cannabis and Cannabinoid Analgesia, which will describe the Task Force’s outputs. The session on 25 March will include an open question and answer session with Task Force providing an opportunity for feedback on the Position Statement. Registration is free for IASP members.
We sincerely thank all the Task Force members for their diligence and exhaustive efforts in contributing to the work delivered.
We also thank the IASP and PAIN staff members who have made invaluable contributions that support the Task Force’s work.
With kind regards, 
Andrew Rice
Chair, IASP Presidential Task Force on Cannabis and Cannabinoid Analgesia
Lars Arendt Nielsen
Immediate Past President, IASP
Facebook TwitterYouTube Linkedin YouTube

International Association for the Study of Pain
1510 H Street NW, Suite 600 | Washington, DC 20005 | USA
+1.202.856.7400 |
www.iasp-pain.org  |  Email



chris@csa.co.za
By chris@csa.co.za April 2, 2021 11:14

Log In